Clinical Trials Sponsored by Hanhui Pharmaceuticals CO., LTD

Total 3901 results

Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-small Cell Lung Cancer | Brain Metastases

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Healthy Subjects

China
JCR Pharmaceuticals Co., Ltd.

Recruiting

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Mucopolysaccharidosis III-A

Germany
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer

Pancreatic Cancer | KRAS P.G12C

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of BPI-452080 in Subjects With Solid Tumors

Renal Cell Carcinoma | Solid Tumor | Von Hippel-Lindau Disease

China
Ascletis Pharmaceuticals Co., Ltd.

Not yet recruiting

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

SARS CoV 2 Infection

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Lymphoma | HCC | NSCLC | Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12C

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Non-small Cell Lung Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Advanced Colorectal Cancer | Small Intestinal Cancer | Appendiceal Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China

NSCLC | Solid Tumor | CRC

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
JCR Pharmaceuticals Co., Ltd.

Recruiting

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Mucopolysaccharidosis II

United States, Germany, Spain, France, Brazil, Argentina, Turkey, United Kingdom, Poland, Italy
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
JCR Pharmaceuticals Co., Ltd.

Enrolling by invitation

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

Mucopolysaccharidosis II

United States
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Non-Small Cell Lung Cancer | EGFR Gene Mutation

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Non-Small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
JCR Pharmaceuticals Co., Ltd.

Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II

Japan
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (ICAPE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors

Solid Tumors

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
TaiwanJ Pharmaceuticals Co., Ltd

Completed

Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

Autoimmune Hepatitis

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Healthy

China
Foresee Pharmaceuticals Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Prostatic Neoplasms

Korea, Republic of, United States, Lithuania, Slovakia, Czechia
Betta Pharmaceuticals Co., Ltd.

Unknown

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Lung Cancer | ROS1 Gene Rearrangement

China
Betta Pharmaceuticals Co., Ltd.

Completed

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (Convince)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalating Study of BPI-3016 in Healthy Subjects

Healthy Subject

China
Foresee Pharmaceuticals Co., Ltd.

Completed

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Healthy

Netherlands
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP)

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
SBI Pharmaceuticals Co, Ltd.

Completed

Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes

Diabetes Mellitus, Type 2
Betta Pharmaceuticals Co., Ltd.

Unknown

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (CHALLENGE)

Plasma EGFR Mutation-positive Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Non-small-cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Pancreatic Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Tianjin Hemay Pharmaceutical Co., Ltd

Recruiting

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Breast Cancer

China
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects (Hemay005)

Psoriasis

China
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Atopic Dermatitis

China
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

HER2 Positive Breast Cancer

China
Tianjin Hemay Pharmaceutical Co., Ltd

Terminated

A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Behçet Disease

China
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Betta Pharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd

Completed

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Psoriasis

China

3

Subscribe